Koers Immunoprecise Antibodies Ltd Toronto S.E.
Aandelen
TQY
CA87588T2020
Farmaceutische producten
Omzet 2024 * | 24,59 mln. 17,86 mln. 16,61 mln. | Omzet 2025 * | 29,82 mln. 21,66 mln. 20,15 mln. | Marktkapitalisatie | 35,83 mln. 26,03 mln. 24,21 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -8,72 mln. -8,11 mln. | Nettowinst (verlies) 2025 * | -9 mln. -6,54 mln. -6,08 mln. | EV/omzet 2024 * | 1,46 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,2 x |
K/w-verhouding 2024 * |
-2,82
x | K/w-verhouding 2025 * |
-3,82
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,41% |
Recentste transcriptie over Immunoprecise Antibodies Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29-09-23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05-09-23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,82% | 91,94 mld. | |
-3,16% | 38,74 mld. | |
+64,83% | 26,66 mld. | |
-12,55% | 15,32 mld. | |
-5,92% | 13,3 mld. | |
-11,38% | 11,65 mld. | |
+156,85% | 10,37 mld. | |
-49,84% | 10,12 mld. | |
+2,32% | 9,06 mld. |